Back to today’s briefing

Story perspectives

Trump Launches Investigation into Pharma Imports' Security Risks

4/19/2025

44 6

Summary

Story summary

President Trump's administration is launching a Section 232 investigation to assess the national security risks posed by pharmaceutical imports. This critical inquiry may result in new tariffs, affecting drug prices and supply chains. The pharmaceutical industry has until May 7 to voice their concerns to the Department of Commerce, shaping the future of this investigation.

1 of 1

Story summary

President Trump's administration is launching a Section 232 investigation to assess the national security risks posed by pharmaceutical imports. This critical inquiry may result in new tariffs, affecting drug prices and supply chains. The pharmaceutical industry has until May 7 to voice their concerns to the Department of Commerce, shaping the future of this investigation.